Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment

NARecruitingINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2028

Conditions
Hepatocellular Carcinoma
Interventions
DIAGNOSTIC_TEST

AMRI

The study subjects will receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination will be conducted using a 3-Tesla MRI machine, and the MRI protocol consists of T2-weighted imaging,diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.

DIAGNOSTIC_TEST

CT

CT will be performed by obtaining dynamic phases (precontrast phase, arterial phase, portal venous phase, and delayed phase images). Subjects will receive intravenous injection of iodine contrast media. Scan coverage was from the basal lung to the iliac crest or pelvis.

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER